BioWorld

Jan. 7, 2002

Abgenix Drops ABX-IL8 For RA Following Phase II Trial Results

Abgenix Inc. s stock took a small hit Friday following the disclosure that a Phase IIa study of its rheumatoid arthritis candidate failed to meet its endpoints. Read More

Aurora, Allergan Expand Work To Include GPCR Screening

Industry, Academia Knock Out Immune Rejection Gene From Porcine Xenotransplant Grafts

Acadia Partners With Amgen To Discover Small-Molecule Drugs

Other News To Note

3-D Pharma, J&J Collaborate On Small-Molecule Drug Discovery

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...